Clinical Trials Logo

Persistent Disease clinical trials

View clinical trials related to Persistent Disease.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT04049539 Recruiting - Clinical trials for Refractory Acute Myeloid Leukemia

Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction

Start date: January 29, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This phase II trial studies the side effects and how well Vyxeos works in treating patients with intermediate and high-risk acute myeloid leukemia who have failed an initial cycle of standard cytarabine and daunorubicin chemotherapy. Vyxeos is a combination of both chemotherapy drugs cytarabine and daunorubicin contained in a liposome. Drugs used in chemotherapy, such as cytarabine and daunorubicin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Cytarabine and daunorubicin given together in liposomes may have fewer side effects and work better than cytarabine and daunorubicin given alone in patients with acute myeloid leukemia.